July 11th 2025
Panelists discuss how the evolving treatment landscape, including CAR T-cell therapy and bispecifics, has made it possible to offer cellular therapies like cilta-cel as early as second-line treatment for eligible patients.
Panelists discuss how novel agents like iberdomide show promising efficacy and manageable toxicity in early-phase studies for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
July 4th 2025
Panelists discuss how isatuximab-containing quadruplet regimens offer clinical benefit in patients with 1q gain or amplification, though its advantage appears to reflect a class effect among CD38-targeting agents.
June 27th 2025
Panelists analyses from the CEPHEUS suggest that quadruplet regimens provide broad benefits in transplant-ineligible patients, though ultra–high-risk subtypes may require novel strategies discuss how subgroup.
Panelists discuss how treating newly diagnosed, transplant-ineligible multiple myeloma patients requires a nuanced approach that accounts for comorbidities, age, and functional status to optimize induction therapy.
June 20th 2025
Panelists discuss how data from the PERSEUS trial supports the use of daratumumab in quadruplet regimens to improve sustained minimal residual disease negativity and progression-free survival in transplant-eligible myeloma patients.
Panelists discuss how quadruplet-based induction therapy, including anti-CD38 monoclonal antibodies, is becoming the preferred frontline treatment for transplant-eligible patients with multiple myeloma based on risk stratification.
September 11th 2023
Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.
August 1st 2023
Luciano J. Costa, MD, PhD, discusses the background of the phase 2 MASTER trial in newly diagnosed multiple myeloma.
June 21st 2023
Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.
June 16th 2022
Closing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.
Luciano Costa, MD, and Adriana Rossi, MD, consider the possibility of earlier-line bispecific and CAR T-cell therapies in multiple myeloma.
June 9th 2022
In light of emerging bispecific and CAR T-cell therapies in multiple myeloma, experts consider how they might optimally sequence treatment.
Comprehensive discussion on the MonumenTAL-1 trial of talquetamab, a GPRC5D- and CD3-targeted agent, in the setting of relapsed/refractory multiple myeloma.
June 2nd 2022
Moving on to the second clinical scenario of multiple myeloma, Luciano Costa, MD, details his care of a heavily pretreated patient.
Expert perspectives on the MajesTEC-1 trial, a study of BCMA- and CD3-targeted agent teclistamab in relapsed/refractory multiple myeloma.
May 26th 2022
Shared insight on factors that help to determine optimal therapy for patients diagnosed with triple-class refractory multiple myeloma.
Expert hematologist-oncologist Adriana Rossi, MD, shares a real-world patient scenario of triple-class refractory multiple myeloma managed with novel bispecific antibody therapy.
April 28th 2021
Luciano J. Costa, MD, PhD, discusses the rationale to develop later-line therapies for use in the frontline setting in multiple myeloma.